NEW ORLEANS–(BUSINESS WIRE)–Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the
law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the
proposed sale of Aratana Therapeutics (NasdaqGM: PETX) (“Aratana”) to
Elanco Animal Health (NYSE: ELAN) (“Elanco”). Under the terms of the
proposed transaction, shareholders of Aratana will receive only 0.1481
shares of Elanco and one contingent value right valued at $0.25 for each
share of Aratana that they own. KSF is seeking to determine whether this
consideration and the process that led to it are adequate, or whether
the consideration undervalues the Company.
If you believe that this transaction undervalues the Company and/or if
you would like to discuss your legal rights regarding the proposed sale,
you may, without obligation or cost to you, e-mail or call KSF Managing
Partner Lewis S. Kahn ([email protected])
toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgm-petx/
to learn more.
To learn more about KSF, whose partners include the Former Louisiana
Attorney General, visit www.ksfcounsel.com.
Contacts
Kahn Swick & Foti, LLC
Lewis S. Kahn, Managing Partner,
855-768-1857
[email protected]
